期刊
ONCOGENE
卷 36, 期 45, 页码 6272-6281出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2017.225
关键词
-
资金
- Grants of the Cell Innovation Program
- P-Direct from the MEXT, Japan
- JSPS, Japan
- MHLW, Japan
- Program for Promotion of Fundamental Studies in Health Sciences
- NIBIO, Japan
- Takeda Science Foundation
- Mochida Memorial Research Foundation, Japan
- Yasuda Memorial Foundation
- Princess Takamatsu Cancer Research Fund
- Grants-in-Aid for Scientific Research [15K15581, 15K10610] Funding Source: KAKEN
The androgen receptor (AR) has a central role in prostate cancer progression, particularly treatment-resistance disease including castration-resistant prostate cancer. Loss of the p53 tumor suppressor, a nuclear transcription factor, is also known to contribute to prostate malignancy. Here we report that p53 is translocated to the cytoplasm by androgen-mediated induction of G3BP2, a newly described direct target gene of AR. G3BP2 induces both cell cycle progression and blocks apoptosis. Translocation of p53 is regulated by androgen-dependent sumoylation mediated by the G3BP2-interacting SUMO-E3 ligase, RanBP2. G3BP2 knockdown results in reduced tumor growth and increased nuclear p53 accumulation in mouse xenograft models of prostate cancer with or without long-term androgen deprivation. Moreover, strong cytoplasmic p53 localization is correlated clinically with elevated G3BP2 expression and predicts poor prognosis and disease progression to the hormone-refractory state. Our findings reveal a new AR-mediated mechanism of p53 inhibition that promotes treatment-resistant prostate cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据